Genfit S.A. (EPA:GNFT – Get Free Report)’s share price was down 2.9% during mid-day trading on Tuesday . The stock traded as low as €3.95 ($4.16) and last traded at €3.98 ($4.19). Approximately 239,671 shares traded hands during trading, The stock had previously closed at €4.10 ($4.32).
Genfit Stock Performance
The firm has a fifty day moving average price of €4.89 and a 200 day moving average price of €4.30.
Genfit Company Profile
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
- Five stocks we like better than Genfit
- What is a support level?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How Investors Can Find the Best Cheap Dividend Stocks
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
